Do beliefs about the pathogenetic role of amyloid affect the interpretation of amyloid PET in the clinic?

M. Boccardi, D. Altomare, C. Ferrari, C. Festari, L. Antelmi, M. Pievani, A. Tarallo, C. Muscio, U.P. Guerra, B. Paghera, A. Padovani, G.B. Frisoni, O. Zanetti, Gian Paolo Anzola, M. Bertocchi, E. Chitò, S. Galluzzi, C. Geroldi, Giulia Lussignoli, F. MattioliD. Moretti, C. Pizzocaro, B. Borroni, L. Rozzini, A. Prelle, Michele Gennuso, D. Villani, M.C. Raimondi, S. Gentile, G. Bellelli, A. Morandi, R. Turco, D. Bellandi, P. P. Carbone, Luciano Abruzzi, Lorenzo Bettoni, A. Bianchetti, E. Facchi, Ignazio Di Fazio, M. Turla, M.S. Cotelli, Giorgio Dalla Volta, Barbara Bigni, G. Bilotti, Stefano Vollaro, R. Rozzini, S. Boffelli, Michele Cappuccio, M. Z. Conti, Giovanni Guizzetti, C. A. Defanti, D. Mirabile, S. Fascendini, L. Manzoni, Gian Pietro Salvi, G. Belotti, S. Cavaliere, F. Fiacco, Allyson L. Valente, A. Ciccone, De A. Lanari, L. Selletti, Francesco Palmerini, S. Avanzi, Giuliana Vezzadini

Research output: Contribution to journalArticle

Abstract

Background: Beliefs of dementia experts about the pathogenic role of amyloid in Alzheimer's disease (AD) may affect the use of amyloid positron emission tomography (PET). Objective: To assess the role attributed to amyloid in AD pathogenesis by Italian dementia experts, and whether this modulates the impact of amyloid PET results in their diagnostic workup. Methods: 22 dementia experts rated their beliefs about the pathogenic role of amyloid. Then, we asked them to rate the probability of change in diagnosis based on the result of amyloid PET for 7 case vignettes, depicting patients who initially received a diagnosis based on a comprehensive workup and later received amyloid PET results consistent or inconsistent with the clinical picture. Results: 55% of the experts assigned a dominant role to amyloid, and 32% attributed a similar role to amyloid and tau in AD pathogenesis. The probability of change in diagnosis ranged from 17% (SD = 21.6) for cases with consistent to 51% (SD = 34) for cases with inconsistent PET versus clinical data. Diagnostic change was not biased by the clinicians' beliefs about AD pathogenesis. Conclusions: This work supports an unbiased interpretation of amyloid PET across different beliefs about the pathogenic role of amyloid, and a belief-independent reluctance to change diagnosis in cases where change is expected and recommended. © 2015 S. Karger AG, Basel.
Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalNeurodegenerative Diseases
Volume16
Issue number1-2
DOIs
Publication statusPublished - 2016

    Fingerprint

Keywords

  • Alzheimer's disease pathogenesis
  • Amyloid positron emission tomography
  • Differential diagnosis
  • Incremental diagnostic value
  • amyloid
  • Alzheimer disease
  • amyloid plaque
  • Conference Paper
  • dementia
  • diagnostic procedure
  • diagnostic value
  • geriatrician
  • human
  • medical specialist
  • neuroimaging
  • neurologist
  • pathogenesis
  • positron emission tomography
  • priority journal
  • probability

Cite this

Boccardi, M., Altomare, D., Ferrari, C., Festari, C., Antelmi, L., Pievani, M., Tarallo, A., Muscio, C., Guerra, U. P., Paghera, B., Padovani, A., Frisoni, G. B., Zanetti, O., Anzola, G. P., Bertocchi, M., Chitò, E., Galluzzi, S., Geroldi, C., Lussignoli, G., ... Vezzadini, G. (2016). Do beliefs about the pathogenetic role of amyloid affect the interpretation of amyloid PET in the clinic? Neurodegenerative Diseases, 16(1-2), 1-7. https://doi.org/10.1159/000439255